Recent developments in bone anabolic therapy for osteoporosis

Baosheng Guo, Songlin Peng, Chao Liang, Xiaojuan He, Cheng Xiao, Cheng Lu, Miao Jiang, Hongyan Zhao, Aiping Lyu, Ge Zhang*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

6 Citations (Scopus)


Osteoporosis is a disorder in which there is a net bone loss and microarchitectural deterioration with an increased risk of bone fracture because of uncoupling of bone formation and bone resorption. The treatment of osteoporosis aims to inhibit bone resorption by osteoclasts and/or promote bone formation by osteoblasts. However, most of the current approaches for treating osteoporosis focus on inhibiting bone resorption. As the only US FDA-approved anabolic agent, the recombinant human parathyroid hormone is recommended for consecutive 2-year period treatment in a clinical setting. Therefore, it is highly desirable to identify novel bone anabolic agents or approaches for osteoporosis treatment. In this review, the authors introduce a new bone anabolic therapy by means of RNAi strategy. Specifically, the authors also discuss the current status and perspectives for RNAi as a novel anabolic approach in the treatment of osteoporosis.

Original languageEnglish
Pages (from-to)677-685
Number of pages9
JournalExpert Review of Endocrinology and Metabolism
Issue number6
Publication statusPublished - Nov 2012

Scopus Subject Areas

  • Endocrinology, Diabetes and Metabolism

User-Defined Keywords

  • anabolic agents
  • BMP signaling
  • osteoporosis
  • RNAi
  • Wnt signaling


Dive into the research topics of 'Recent developments in bone anabolic therapy for osteoporosis'. Together they form a unique fingerprint.

Cite this